393 476
Table 2 – Persistence and adherence: mirabegron versus tolterodine ER (unmatched analysis)
Variable
All patients
Treatment-naı¨ve patients
Treatment-experienced patients
Elderly patients
Mirabegron
(
n
= 1203)
Tolterodine
ER (
n
= 1561)
Mirabegron
(
n
= 476)
Tolterodine
ER (
n
= 1150)
Mirabegron
(
n
= 411)
Tolterodine
ER (
n
= 727)
Mirabegron
(
n
= 661)
Tolterodine
ER (
n
= 876)
Persistence
Time to discontinuation (d)
Median (IQR)
169 (41–NR)
56 (28–254)
132 (30–NR)
56 (28–168)
189 (56–NR)
120 (28–581)
202 (52–NR)
56 (28–264)
Hazard ratio (95% CI)
a1.55 (1.41–1.71)
1.66 (1.46–1.88)
1.41 (1.21–1.63)
1.70 (1.50–1.94)
p
value
<
0.0001
<
0.0001
<
0.0001
<
0.0001
12-mo persistence,
n
(%)
454 (38)
318 (20)
164 (34)
192 (17)
290 (40)
126 (31)
274 (41)
184 (21)
Difference, % (95% CI)
17 (14–21)
18 (13–23)
9 (4–15)
20 (16–25)
Odds ratio (95% CI)
a0.48 (0.40–0.58)
0.39 (0.30–0.50)
0.62 (0.48–0.81)
0.41 (0.32–0.52)
p
value
<
0.0001
<
0.0001
<
0.0001
<
0.0001
Adherence
Patients (
n
)
955
889
345
609
610
280
540
500
MPR
Mean (SD)
b0.59 (0.33)
0.51 (0.33)
0.59 (0.33)
0.48 (0.33)
0.59 (0.34)
0.60 (0.31)
0.61 (0.33)
0.53 (0.33)
p
value
<
0.0001
<
0.0001
0.98
<
0.0001
Adherent patients,
c n(%)
410 (43)
290 (33)
150 (43)
177 (29)
260 (43)
113 (40)
252 (47)
176 (35)
Difference, % (95% CI)
10 (6–15)
14 (8–21)
2 (-5–9)
12 (5–17)
p
value
<
0.0001
<
0.0001
0.52
0.0002
Median follow-up (d)
d525
548
500
531
546
571
515
548
CI = confidence interval; ER = extended release; IQR = interquartile range; MPR = medication possession ratio; NR = not reached; SD = standard deviation.
a
Adjusted for gender, age group, treatment status, Charlson comorbidity index, hypertension, and polypharmacy at index date.
b
MPRs ranged from 0 (no adherence) to 1 (perfect adherence).
c
Patients considered to be adherent when MPR 0.8.
d
Patients who did not discontinue treatment 12 mo after initiation.
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 3 8 9 – 3 9 9
393